Amgen (AMGN) has been active with both ups and downs reflected in its share price and investments. The company has caught attention due to its dividend, developments in obesity drug studies, and cardiovascular trial updates. A partnership with GSK (GSK) through the TrumpRx platform expands the companies' reach. The company's shares have had mixed returns recently, leading to questions about their pricing. Notable movement in shareholding includes Harvest Fund Management, M&T Bank Corp, and Comerica Bank reducing their stake, while others like Invesco Ltd., Bank of Montreal, and Legal & General Group increased their holdings in the company. The company also announced the completion of a Phase 3 trial for ABP 206 Opdivo, a biosimilar candidate. Despite some setbacks such as the halt of Rocatinlimab trial, the company continues to innovate, planning to invest over half a billion dollars in its Centre for Science and Innovation at its global headquarters. Overall, Amgen's financial standing and commitment to innovation show promise, although the company has to navigate through some uncertainties in the market.
Amgen AMGN News Analytics from Tue, 02 Sep 2025 07:00:00 GMT to Sat, 14 Mar 2026 22:36:02 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor 2
